PALO ALTO, Calif., March 10, 2020 /PRNewswire/ -- Varian (NYSE: VAR)
today announced Medisch Spectrum Twente Hospital in The Netherlands, and Icon Cancer Centre
Wahroonga and Royal North Shore Hospital (RNSH) in Australia treated their first patients with
Ethos™ therapy. This artificial intelligence
(AI)-driven holistic adaptive therapy solution is designed to
deliver an entire adapted treatment in a typical 15-minute
timeslot.
Adaptive therapy provides the ability to personalize the
patient's treatment based on their anatomy and position at the time
of treatment. The goal is to better target the tumor, reduce dose
to healthy tissue, and potentially improve overall outcomes.
At Medisch Spectrum Twente Hospital, the first two patients
treated were for prostate cancer, at RNSH the first treatment was
for head and neck cancer and at Icon Cancer Centre Wahroonga, the
first treatment was for prostate cancer. Additionally, since
delivering the first Ethos therapy in the world in September 2019, Herlev and Gentofte
Hospital in Denmark has
already delivered 100 adaptive fractions for bladder cancer
patients.
"Since the launch of Ethos therapy, the response from clinicians
globally has been very strong," said Chris
Toth, president Varian Oncology Systems. "Ethos therapy was
designed to launch a new era of personalized adaptive radiation
therapy and we are very pleased to see patients in Australia and The
Netherlands now have access to these adaptive treatments.
With Ethos therapy recently receiving 510(k) clearance, the first
installation in the US is in process and will be treating patients
soon."
Clinician Experience
"The future is adaptive," said Erik Van
Dieren, head of Medical Physics, Medisch Spectrum Twente
Hospital. "With Ethos we know adaptive radiotherapy on a daily
basis is achievable for a large number of patients due to high
accuracy and excellent sparing of the healthy tissue in about 15
minutes treatment time."
"Early Ethos therapy experience from Icon is showing promising
results," said Amy Teh, MD,
radiation oncologist at Icon Cancer Centre, Wahroonga. "In a
prostate patient, where the target volume is highly dependent on
bladder and rectal positioning, we have used the AI-driven online
adaptive workflow on the Ethos platform to effectively and
efficiently adapt to the new position of the bladder and rectum
each day. This has allowed superior coverage of the true target.
This technology marks another step forward in the advancement of
radiation therapy – taking personalized medicine to another level –
allowing us to ensure more dose to the tumor target, and less dose
to surrounding healthy organs."
"RNSH is very pleased to enter the world of Ethos therapy after
recently treating our first patient," said Jeremy Booth, head of Medical Physics, Northern
Sydney Cancer Centre, RNSH. "The patient treatment for head and
neck cancer was an exceptional experience, uniting our expert team
of radiation therapists, medical physicists and radiation
oncologists at the console to ensure we safely delivered the best
treatment."
"We've found that, with bladder cancer patients, we are seeing
the most impact using online adaptation," said Poul Geertsen, MD, PhD, head of Radiotherapy,
Department of Oncology at Herlev and Gentofte Hospital. "With Ethos
therapy, we are seeing treatment margin reductions of up to 50
percent, which is impressive."
The streamlined workflow of Ethos therapy is enabled by its
AI-driven planning and contouring capabilities. Physicians define
their clinical intent from pre-defined templates and the initial
treatment plan is generated based on the physician's pre-defined
clinical objectives. The treatment is adapted in response to
changes in the patient's anatomy and the tumor's shape and
position, at the time of treatment. The ability of Ethos to enable
on-couch adaptive treatment puts the patient at the center of
care.
Ethos therapy offers the use of multimodality images (MR, PET,
CT) registered with daily iterative CBCT images at the console. By
providing an up-to-date view of the patient's anatomy in multiple
imaging modality views, Ethos therapy provides clinicians the
confidence to make more informed adaptive treatment decisions. The
solution is built on Varian's latest treatment delivery technology
and provides fast imaging and treatment delivery without
compromising quality.
For more information on Ethos, visit www.varian.com/ethos.
About Varian
At Varian, we envision a world without fear of cancer. For more
than 70 years, we have developed, built and delivered innovative
cancer care technologies and solutions for our clinical partners
around the globe to help them treat millions of patients each year.
With an Intelligent Cancer Care approach, we are harnessing
advanced technologies like artificial intelligence, machine
learning and data analytics to enhance cancer treatment and expand
access to care. Our 10,000 employees across 70 locations keep the
patient and our clinical partners at the center of our thinking as
we power new victories in cancer care. Because, for cancer patients
everywhere, their fight is our fight. For more information, visit
http://www.varian.com and follow @VarianMedSys on Twitter.
Customers were not paid for their testimonials. Individual
results may vary
Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/ethos-therapy-continues-global-expansion-301020404.html
SOURCE Varian